Intellia Therapeutics Inc

NTLA

12.280USD

+1.190+10.73%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Intellia Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

107 / 392

Overall Ranking

237 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Intellia Therapeutics Inc Highlights

StrengthsRisks

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.

Growing

The company is in a growing phase, with the latest annual income totaling USD 57.88M.

Fairly Valued

The company’s latest PE is -2.88, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 104.91M shares, decreasing 11.26% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 14.40K shares of this stock.

Analyst Rating

Based on 24 analysts

Hold

Current Rating

23.474

Target Price

+111.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Intellia Therapeutics Inc is 6.85, ranking 198 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 13.78M, representing a year-over-year increase of 51.27%, while its net profit experienced a year-over-year increase of 25.34%.

Score

Industry at a Glance

Previous score

6.85

Change

0



Financials

7.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.97

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.72

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.30

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Intellia Therapeutics Inc is 5.96, ranking 348 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.88, which is -58.37% below the recent high of -1.20 and -197.15% above the recent low of -8.57.

Score

Industry at a Glance

Previous score

5.96

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 107/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Intellia Therapeutics Inc is 6.92, ranking 323 out of 392 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 106.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

6.92

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Intellia Therapeutics Inc is 6.62, ranking 210 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 16.20 and the support level at 9.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.34

Change

0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Intellia Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 90.57%, representing a quarter-over-quarter increase of 12.30%. The largest institutional shareholder is Catherine Wood, holding a total of 14.21M shares, representing 12.27% of shares outstanding, with 2.35% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

11.92M

-8.44%

The Vanguard Group, Inc.

Star Investors

11.02M

+1.78%

BlackRock Institutional Trust Company, N.A.

7.60M

-5.46%

Contrarius Investment Management Ltd.

5.89M

+279.38%

State Street Investment Management (US)

4.97M

+23.06%

Two Sigma Investments, LP

4.61M

+5.57%

Goldman Sachs & Company, Inc.

3.77M

+129.34%

Regeneron Pharmaceuticals Inc

3.70M

--

Morgan Stanley Investment Management Inc. (US)

2.96M

+51.40%

Baker Bros. Advisors LP

2.75M

+2.65%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Intellia Therapeutics Inc is 2.36, ranking 233 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Intellia Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Intellia Therapeutics Inc

NTLA

6.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment